📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-07 19:15
0 analysed today
FollowTelegram
0
Today
151,853
All-time analysed
43,533
Positive
6,742
Negative
92,741
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
6 announcements match the current filters (relevance ≥ 5).
Remus Pharma Shareholders Approve Migration to NSE and BSE Main Boards with 100% In-Favour Votes
Remus Pharmaceuticals shareholders have approved a special resolution via postal ballot to migrate the company's equity shares from the NSE Emerge platform to the Main Boards of NSE and BSE. Out of 2,38,600 public votes polled (representing 2.0248% of total outstanding shares), 100% voted in favor, with zero votes against. Promoters, holding 83,61,200 shares (70.95%), did not vote as required by ICDR regulations for migration proposals. The resolution satisfies SEBI ICDR Regulation 277 requirements, paving the way for official stock exchange migration.
Confidence: HIGH
What changedShareholders have formally approved the migration of Remus Pharmaceuticals from the SME exchange (NSE Emerge) to the Main Boards of NSE and BSE.
Why it mattersMigration to the Main Board typically removes SME trading lot size restrictions, broadens the institutional investor base, and enhances stock liquidity for a ₹753 Cr market cap company.
Total votes cast in favour: 2,38,600Percentage of votes in favour: 100.0000%Promoter shares abstained: 83,61,200Total outstanding shares: 1,17,84,000
📅 Short termPositive sentiment driver as the migration clears shareholder voting; focus shifts to exchange approval timelines.
📈 Long termMain Board listing eliminates SME lot size trading friction, which generally improves retail and institutional participation and overall liquidity.
⚠ Risk flags
- Final approval is subject to regulatory clearance from NSE and BSE.
Key Highlights
Special resolution to migrate from NSE Emerge to NSE & BSE Main Boards passed with 100.0000% votes in favor.
A total of 2,38,600 votes were polled, all cast in favor, with 0 votes against.
Promoter group abstained from voting on their 83,61,200 shares in compliance with SEBI ICDR norms.
Public institutions cast 15,400 votes and public non-institutions cast 2,23,200 votes, both supporting the resolution unanimously.
👀 What to Watch
Track subsequent in-principle and final listing approvals from NSE and BSE, as well as the formal effective date for trading on the Main Board.
Remus Pharma Seeks Shareholder Approval to Migrate to NSE & BSE Main Boards
Remus Pharmaceuticals has issued a Postal Ballot notice seeking shareholder approval to migrate its equity shares from the NSE Emerge platform to the Main Boards of both NSE and BSE. The company originally listed on NSE Emerge on May 29, 2023, meeting the required listing track record under SEBI ICDR Regulations. E-voting will take place from September 07, 2026, to October 06, 2026, with results expected on or before October 08, 2026. The resolution requires public shareholder votes in favor to be at least twice the votes cast against.
Confidence: HIGH
What changedRemus Pharma initiated a formal postal ballot process to transition its listing from the SME platform (NSE Emerge) to the Main Boards of NSE and BSE.
Why it mattersMigration to the main board eliminates SME lot-size trading restrictions, significantly improving trading liquidity, visibility, and eligibility for institutional investors.
Face value per share: Rs. 10.00NSE Emerge listing date: May 29, 2023Record / Cut-off date: August 28, 2026E-voting end date: October 06, 2026Voting result announcement: On or before October 08, 2026
📅 Short termShareholder voting will conclude on October 06, 2026. The approval is largely procedural given the typical alignment on main board migration.
📈 Long termListing on the main boards of NSE and BSE will provide broader institutional participation, higher retail liquidity, and support the company's valuation as scale grows.
⚠ Risk flags
- Requires non-promoter (public) votes in favor to be at least double the votes against
- Final migration remains subject to regulatory and exchange approvals
Key Highlights
Proposed migration of equity shares (face value Rs 10.00) from NSE Emerge to Main Boards of NSE and BSE
SEBI ICDR requirement: Public votes in favor must be at least 2x the votes cast against
E-voting begins on September 07, 2026, and ends on October 06, 2026
Cut-off record date for eligibility set as August 28, 2026; results on or before October 08, 2026
Company originally listed on the NSE Emerge platform on May 29, 2023
👀 What to Watch
Track the outcome of the postal ballot voting on or before October 08, 2026, followed by formal approval and listing dates from NSE and BSE.
Remus approves Main Board migration to NSE & BSE, Dominican Republic subsidiary (>=51% stake)
Remus Pharmaceuticals' Board approved the migration of its equity shares from the NSE Emerge platform to the Main Boards of NSE and BSE, subject to shareholder and regulatory approvals. The company also approved the incorporation of a subsidiary in the Dominican Republic with a minimum 51% equity stake to drive local supply and distribution of pharma products. Additionally, Mr. Ashutosh Naginbhai Valani was appointed as a Non-Executive Independent Director for a 5-year term effective September 02, 2026.
Confidence: HIGH
What changedThe Board approved migration to the Main Board from SME Emerge and initiated incorporation of a >=51% subsidiary in the Dominican Republic.
Why it mattersMain Board listing broadens access to institutional capital and improves trading liquidity, while the overseas subsidiary strengthens international distribution.
Subsidiary shareholding: >=51%Director appointment term: 5 consecutive yearsMarket Cap: Rs 773 CrTTM Revenue: Rs 1239 Cr
📅 Short termPositive sentiment from the Main Board migration milestone, subject to customary shareholder and exchange approvals.
📈 Long termEnhances visibility among institutional investors via Main Board listing and aids Central America/Caribbean geographic expansion.
⚠ Risk flags
- Regulatory approval dependencies for Main Board migration
- Execution and compliance risks in the Dominican Republic market
Key Highlights
Approved migration of equity shares from NSE Emerge platform to the Main Boards of NSE and BSE.
Approved incorporation of a subsidiary in Dominican Republic with Remus holding 51% or more shareholding via cash subscription.
Appointed Mr. Ashutosh Naginbhai Valani as Non-Executive Independent Director for a 5-year term from September 02, 2026.
Remus reported TTM revenue of Rs 1,239 Cr with net worth of Rs 326 Cr.
👀 What to Watch
Track shareholder voting outcomes and subsequent regulatory approvals from NSE and BSE for the Main Board migration timeline.
Remus Approves Main Board Migration, Dominican Republic Subsidiary, Appoints Independent Director
Remus Pharmaceuticals announced three key board approvals on September 2, 2026. The company will seek shareholder and regulatory approval to migrate its listing from the NSE Emerge platform to the Main Boards of NSE and BSE, potentially enhancing liquidity and institutional participation. Additionally, the board approved setting up a new subsidiary in the Dominican Republic with at least a 51% stake to expand its international distribution network. Serial consumer entrepreneur Ashutosh Naginbhai Valani (co-founder of Renee Cosmetics and Beardo) was appointed as an Independent Director for a 5-year term.
Confidence: HIGH
What changedRemus initiated its migration from SME platform to NSE/BSE Main Board, established an overseas foothold in the Dominican Republic, and onboarded Ashutosh Valani to its board.
Why it mattersMain Board listing can expand institutional investor access, while geographic expansion into the Dominican Republic builds on the company's export-driven formulations strategy.
Proposed subsidiary stake: 51% or moreIndependent Director term: 5 (Five) consecutive yearsEffective date of appointment: September 02, 2026
📅 Short termPositive for sentiment as Main Board migrations typically widen investor eligibility and trading volume.
📈 Long termStructural positive for liquidity and governance profile, while the Dominican subsidiary deepens presence in Central America/Caribbean markets.
⚠ Risk flags
- Subject to shareholder and exchange approvals for Main Board migration
- Execution and regulatory risks in the Dominican Republic market
Key Highlights
Approved migration of listing from NSE Emerge to the Main Boards of NSE and BSE, subject to approvals.
Approved incorporation of a pharmaceutical supply and distribution subsidiary in the Dominican Republic with >=51% equity holding.
Appointed Mr. Ashutosh Naginbhai Valani as Non-Executive Independent Director for a 5-year term effective September 02, 2026.
👀 What to Watch
Track shareholder voting outcomes and exchange filing approvals for the Main Board migration timeline, alongside initial capital deployment updates for the Dominican Republic entity.
Remus Pharma approves Main Board migration, new Dominican Republic subsidiary, and director
Remus Pharmaceuticals has approved the migration of its listing from the NSE Emerge platform to the Main Boards of NSE and BSE, subject to shareholder and regulatory approvals. The Board also approved the incorporation of a subsidiary in the Dominican Republic, in which Remus will hold a 51% or higher equity stake via cash consideration. Additionally, entrepreneur Ashutosh Naginbhai Valani (co-founder of Renee Cosmetics, Beardo) was appointed as an Independent Director for a 5-year term.
Confidence: HIGH
What changedThe company initiated steps to graduate from SME (NSE Emerge) to the Main Board and greenlit a new distribution subsidiary in the Dominican Republic.
Why it mattersMain Board migration typically enhances trading liquidity, institutional investor eligibility, and visibility. The Dominican Republic subsidiary deepens the company's export footprint in Latin America and the Caribbean.
Proposed subsidiary ownership: 51% or moreDirector appointment term: 5 consecutive yearsTTM Revenue: Rs 1239 CrMarket Cap: Rs 773 Cr
📅 Short termPositive sentiment driven by the planned Main Board migration and governance strengthening via an experienced consumer brand entrepreneur joining the board.
📈 Long termExpands geographic reach into the Caribbean/Latin America to complement ongoing export filings and enhances retail and institutional participation following the Main Board listing.
⚠ Risk flags
- Requires regulatory approvals and shareholder consent for Main Board migration
- Execution and compliance risks in navigating Dominican Republic pharmaceutical regulations
Key Highlights
Approved migration of listing from NSE Emerge to the Main Boards of NSE and BSE
To establish a subsidiary in Dominican Republic with >=51% equity holding for supply and distribution
Appointed Ashutosh Naginbhai Valani as Independent Director for a 5-year consecutive term w.e.f. September 02, 2026
Board meeting commenced at 04:30 PM and concluded at 05:30 PM on September 02, 2026
👀 What to Watch
Track shareholder voting outcomes for the Main Board migration and subsequent exchange approval timelines, along with updates on capital commitment for the Dominican Republic entity.
Remus Approves Migration to NSE & BSE Main Boards, New Subsidiary in Dominican Republic
Remus Pharmaceuticals has approved the migration of its securities from the NSE Emerge SME platform to the Main Boards of both NSE and BSE, subject to shareholder and regulatory approvals. The Board also approved the incorporation of a subsidiary in the Dominican Republic (holding at least 51% equity) to expand pharmaceutical supply and distribution in the region. Additionally, Ashutosh Naginbhai Valani (Co-founder of Renee Cosmetics and former founder of Beardo) was appointed as an Independent Director for a 5-year term.
Confidence: HIGH
What changedRemus Pharmaceuticals initiated the process to migrate from the SME platform to the Main Boards of NSE/BSE and authorized setting up an overseas subsidiary in the Dominican Republic.
Why it mattersGraduating to the Main Board eliminates SME lot-size constraints, expanding retail and institutional participation, while the Dominican Republic unit supports international market penetration.
Dominican Republic subsidiary stake: 51% or moreIndependent Director tenure: 5 yearsMarket Cap: ₹773 CrTTM Revenue: ₹1239 Cr
📅 Short termPositive sentiment driver as main board migration improves institutional visibility and trading liquidity once procedural approvals conclude.
📈 Long termEnhances corporate governance via independent board appointments and broadens geographic distribution footprint in Central America/Caribbean.
⚠ Risk flags
- Subject to shareholder and exchange regulatory approvals for migration
- Local regulatory clearances required for incorporation and operations in the Dominican Republic
Key Highlights
Approved migration of equity shares from NSE Emerge SME platform to Main Boards of NSE and BSE.
Proposed incorporation of a Dominican Republic subsidiary with a minimum 51% equity stake via cash consideration.
Appointed Ashutosh Naginbhai Valani as Non-Executive Independent Director for a 5-year term effective September 02, 2026.
Migration is subject to necessary shareholder and stock exchange regulatory approvals.
👀 What to Watch
Track shareholder voting results and subsequent in-principle listing approvals from NSE and BSE regarding the main board migration timeline.
